Zelira Therapeutics Ltd (ZLD) - Net Assets
Based on the latest financial reports, Zelira Therapeutics Ltd (ZLD) has net assets worth AU$-4.29 Million AUD (≈ $-3.04 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.30 Million ≈ $920.32K USD) and total liabilities (AU$5.59 Million ≈ $3.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ZLD financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-4.29 Million |
| % of Total Assets | -329.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -111.34% |
| 10-Year Change | N/A |
| Growth Volatility | 249.3 |
Zelira Therapeutics Ltd - Net Assets Trend (2004–2025)
This chart illustrates how Zelira Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Zelira Therapeutics Ltd (ZLD) total assets for the complete picture of this company's asset base.
Annual Net Assets for Zelira Therapeutics Ltd (2004–2025)
The table below shows the annual net assets of Zelira Therapeutics Ltd from 2004 to 2025. For live valuation and market cap data, see ZLD market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$-4.29 Million ≈ $-3.04 Million |
-2.81% |
| 2024-06-30 | AU$-4.17 Million ≈ $-2.95 Million |
-113.16% |
| 2023-06-30 | AU$31.71 Million ≈ $22.44 Million |
-11.15% |
| 2022-06-30 | AU$35.69 Million ≈ $25.25 Million |
-5.65% |
| 2021-06-30 | AU$37.83 Million ≈ $26.77 Million |
+9.50% |
| 2020-06-30 | AU$34.55 Million ≈ $24.44 Million |
+1011.56% |
| 2019-06-30 | AU$3.11 Million ≈ $2.20 Million |
-49.99% |
| 2018-06-30 | AU$6.21 Million ≈ $4.40 Million |
-21.30% |
| 2017-06-30 | AU$7.90 Million ≈ $5.59 Million |
+3991.72% |
| 2016-06-30 | AU$-202.91K ≈ $-143.57K |
-156.70% |
| 2015-06-30 | AU$357.87K ≈ $253.22K |
-52.29% |
| 2014-06-30 | AU$750.16K ≈ $530.78K |
-27.90% |
| 2013-06-30 | AU$1.04 Million ≈ $736.13K |
-23.06% |
| 2012-06-30 | AU$1.35 Million ≈ $956.78K |
+104.46% |
| 2011-06-30 | AU$661.35K ≈ $467.95K |
+1.07% |
| 2010-06-30 | AU$654.33K ≈ $462.98K |
-73.60% |
| 2009-06-30 | AU$2.48 Million ≈ $1.75 Million |
+94.19% |
| 2008-06-30 | AU$1.28 Million ≈ $902.96K |
+108.60% |
| 2007-06-30 | AU$-14.84 Million ≈ $-10.50 Million |
-199.78% |
| 2006-06-30 | AU$14.88 Million ≈ $10.53 Million |
+50.57% |
| 2005-06-30 | AU$9.88 Million ≈ $6.99 Million |
+19.18% |
| 2004-06-30 | AU$8.29 Million ≈ $5.87 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zelira Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8485202800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$45.52 Million | % |
| Other Comprehensive Income | AU$34.98 Million | % |
| Other Components | AU$2.00 | % |
| Total Equity | AU$-4.46 Million | 100.00% |
Zelira Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Zelira Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CirChem AB
ST:CIRCHE
|
$4.21 Million |
|
Hopening SA
PA:MLHPE
|
$4.22 Million |
|
Mountview Estates PLC
LSE:MTVW
|
$4.22 Million |
|
G Capital Public Company Limited
BK:GCAP
|
$4.22 Million |
|
Lexus Granito (India) Limited
NSE:LEXUS
|
$4.21 Million |
|
Austin Metals Ltd
AU:AYT
|
$4.20 Million |
|
Ecora Resources PLC
LSE:ECOR
|
$4.19 Million |
|
Dimet (Siam) Public Company Limited
BK:DIMET
|
$4.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zelira Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -4,514,925 to -4,460,427, a change of 54,498.
- Net loss of 3,627,872 reduced equity.
- Share repurchases of 2,401 reduced equity.
- Other comprehensive income increased equity by 3,678,220.
- Other factors increased equity by 6,551.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-3.63 Million | -81.33% |
| Share Repurchases | AU$2.40K | -0.05% |
| Other Comprehensive Income | AU$3.68 Million | +82.46% |
| Other Changes | AU$6.55K | +0.15% |
| Total Change | AU$- | % |
Book Value vs Market Value Analysis
This analysis compares Zelira Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | AU$7591.40 | AU$0.50 | x |
| 2005-06-30 | AU$7628.93 | AU$0.50 | x |
| 2006-06-30 | AU$6817.35 | AU$0.50 | x |
| 2007-06-30 | AU$-6016.79 | AU$0.50 | x |
| 2008-06-30 | AU$46.99 | AU$0.50 | x |
| 2009-06-30 | AU$14.25 | AU$0.50 | x |
| 2010-06-30 | AU$1.95 | AU$0.50 | x |
| 2011-06-30 | AU$1.97 | AU$0.50 | x |
| 2012-06-30 | AU$4.22 | AU$0.50 | x |
| 2013-06-30 | AU$1.89 | AU$0.50 | x |
| 2014-06-30 | AU$1.36 | AU$0.50 | x |
| 2015-06-30 | AU$0.65 | AU$0.50 | x |
| 2016-06-30 | AU$-0.31 | AU$0.50 | x |
| 2017-06-30 | AU$2.79 | AU$0.50 | x |
| 2018-06-30 | AU$1.44 | AU$0.50 | x |
| 2019-06-30 | AU$0.72 | AU$0.50 | x |
| 2020-06-30 | AU$7.13 | AU$0.50 | x |
| 2021-06-30 | AU$5.70 | AU$0.50 | x |
| 2022-06-30 | AU$4.38 | AU$0.50 | x |
| 2023-06-30 | AU$3.16 | AU$0.50 | x |
| 2024-06-30 | AU$-0.40 | AU$0.50 | x |
| 2025-06-30 | AU$-0.39 | AU$0.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zelira Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -553029.27%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-28.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -0.31% | -5.10% | 0.06x | 1.03x | AU$-854.56K |
| 2005 | -3.15% | -54.73% | 0.06x | 1.01x | AU$-1.30 Million |
| 2006 | -6.06% | -640.65% | 0.01x | 1.78x | AU$-2.39 Million |
| 2007 | 0.00% | -181.04% | 2.27x | 0.00x | AU$-36.68 Million |
| 2008 | 988.48% | 54845.95% | 0.02x | 1.10x | AU$12.49 Million |
| 2009 | -817.96% | -15713.81% | 0.04x | 1.43x | AU$-20.52 Million |
| 2010 | -257.97% | -4928.45% | 0.05x | 1.06x | AU$-1.75 Million |
| 2011 | 1.06% | 1.41% | 0.57x | 1.32x | AU$-59.11K |
| 2012 | -47.18% | -2199.86% | 0.02x | 1.06x | AU$-773.18K |
| 2013 | -29.97% | -1075.32% | 0.03x | 1.04x | AU$-415.88K |
| 2014 | -38.69% | -1381.99% | 0.03x | 1.04x | AU$-365.23K |
| 2015 | -111.79% | -3451.94% | 0.03x | 1.14x | AU$-435.87K |
| 2016 | 0.00% | -32917.11% | 0.03x | 0.00x | AU$-878.35K |
| 2017 | -77.98% | -3670.37% | 0.02x | 1.01x | AU$-6.95 Million |
| 2018 | -27.84% | -308.13% | 0.09x | 1.02x | AU$-2.35 Million |
| 2019 | -93.22% | -337.21% | 0.24x | 1.13x | AU$-3.21 Million |
| 2020 | -20.31% | -1057.57% | 0.02x | 1.04x | AU$-10.47 Million |
| 2021 | -22.60% | -1288.84% | 0.02x | 1.04x | AU$-12.33 Million |
| 2022 | -33.93% | -775.35% | 0.04x | 1.07x | AU$-15.47 Million |
| 2023 | -17.52% | -1850.75% | 0.01x | 1.07x | AU$-8.75 Million |
| 2024 | 0.00% | -38513.04% | 0.02x | 0.00x | AU$-36.12 Million |
| 2025 | 0.00% | -553029.27% | 0.00x | 0.00x | AU$-3.18 Million |
Industry Comparison
This section compares Zelira Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,810,720
- Average return on equity (ROE) among peers: -71.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zelira Therapeutics Ltd (ZLD) | AU$-4.29 Million | -0.31% | N/A | $4.21 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $105.70 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About Zelira Therapeutics Ltd
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more